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Psychedelic Research Resurgence 
 
Andrew Demosthenous
Introduction 
 
In the 1960s, more than 1,000 peer-reviewed 
research articles detailed the therapeutic use of 
psychedelic compounds. Passage of the Controlled 
Substance Act of 1970 classified psychedelic 
substances such as LSD, MDMA and Psilocybin as 
Schedule 1 drugs with no medical value, 
interrupting research into the application of 
psychedelic compounds for well-being. New 
studies from institutions such as New York 
University, Purdue University, Harvard University, 
and Johns Hopkins University are producing 
evidence that use of these drugs in combination 
with psychotherapy may have potential value for 
treating mental illnesses such as addiction, mood, 
affective, and psychotic disorders. This study 
explores the relationship between the effects of 
these drugs on well-being and the FDA scheduling 
of these drugs at the highest level. Analyses of six 
open-ended interviews with a snowball sample of 
college students about their recreational 
experiences with LSD, MDMA and Psilocybin 
found that college students use these drugs as a tool 
for spiritual and emotional development. They 
reported positive transformative experiences and 
improved relationships with family and friends. 
These findings support the continued expansion of 
research on psychedelic assisted psychotherapy for 
treatment of mental illness and the rescheduling of 
medically beneficial psychedelics by the FDA.   
 
Hallucinogens 
 
“Hallucinogens are substances that cause 
powerful changes in sensory perception, from 
strengthening a person’s normal perceptions to 
inducing illusions and hallucinations” (Comer 
2010, p. 389). These substances, also known as 
psychedelic drugs, include LSD (Lysergic Acid 
Diethylamide), Psilocybin (4-phosphoryloxy-N,N-
dimethyltryptamine), and MDMA (3,4-
methylenedioxymethamphetamine). Many people 
use different definitions for hallucinogens and 
include different types of drugs into those 
definitions. For the purpose of this paper, the  
hallucinogens being discussed will be the 
substances which affect serotonin (5-HT) type 
receptors. Many hallucinogens are found naturally 
in plants and animals. Evolution of tools in 
chemistry and the scientific method in the 1900s 
supported the process of synthesizing new 
hallucinogens. 
With the enactment of the Controlled 
Substances Act of 1970, hallucinogens, among 
them LSD and Psilocybin, were classified as 
schedule I drugs by the United States congress 
(U.S. Drug Enforcement Agency 2010). In 1984, 
MDMA was added by the Drug Enforcement 
Agency (Baum 1997, p. 213).The schedule of the 
drugs, I being the highest and V being the lowest, 
determines the regulatory measures enforced by the 
United States DEA. The higher the drug 
scheduling, the stricter the policies are regarding 
manufacturing, importation, possession, 
distribution, and research for that particular drug. 
Placing LSD, Psilocybin and MDMA in the 
schedule I classification disrupted research on the 
application of hallucinogens to well-being and 
mental health. This also fostered the strictest 
judicial consequences for possession and 
distribution. Both using and distributing LSD are 
felonies. Anyone caught distributing LSD can get 
up to forty years in a federal penitentiary and a two 
million dollar fine (National Geographic 2009). 
Three criteria the United States DEA and FDA 
use for determining if a substance should be 
classified as schedule I are: 1) the drug has no 
accepted medical use in the United States; 2) there 
is a lack of safety for use of the drug under medical 
supervision; 3) the substance has a high “potential 
for abuse” (Nichols 2003, p. 133). “Potential for 
abuse,” an ambiguous criterion, is typically 
interpreted by the United States DEA and FDA as 
the potential for addiction. 
The FDA system of scheduling has been 
heavily criticized due to the influence of politics. 
President Nixon in the early 1970’s took 
responsibility for drug scheduling away from the 
Surgeon General and his team of medical experts. 
The responsibility was delegated instead to the 
office of the attorney general and his team of law 
enforcement experts. Since then, “cops and lawyers 
instead of doctors were judging the toxicity of 
drugs” (Baum 1997, p. 25-26). Decisions made by 
the U.S. attorney general’s office regarding the 
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scheduling of drugs were more heavily influenced 
by the politics of the war on drugs than scientific 
data presented by doctors. For example, in the 
hearings held by the DEA in 1986 regarding the 
scheduling of MDMA, thirty-four witnesses, 
including experts in the field of psychology and 
psychiatry, gave testimony and a ten volume report 
outlining the potential medical benefits of MDMA, 
asking for its rank to be lowered to schedule III. 
DEA Administrative Law Judge Francis Young 
wrote a ninety page opinion paper highlighting the 
witness’ findings and agreed that MDMA should be 
dropped to schedule III, IV or V because of its 
potential medical value in mental health. Despite 
the overwhelming evidence and the agreement by 
Judge Young that the law should be changed, Judge 
Young reinstated his original ban on MDMA, 
leading to the permanent placement of MDMA in 
Schedule I of the Controlled Substances Act in 
1986 (Stafford 1992, p. III-63). 
There is also evidence that the government 
was aware of this inaccurate evaluation of LSD’s 
danger because the CIA had conducted multiple 
experiments on American and British military 
personnel. From 1947 to 1977 the CIA had 
conducted operations coded MKSEARCH, 
MKOFTEN, MKCHICKWIT, MKULTRA, 
MKDELTA, and MK NAOMI (General Council of 
the Department of Defense 1977). Their goal was 
to use LSD as a covert weapon to cause brain  
damage or permanent insanity to the enemy. Their 
other goal was to use LSD as a mind control agent 
or torture device for prisoners in order to obtain 
information (Greenberg 2010, p. 164) (National 
Geographic Documentary 2009). It would have 
been the perfect weapon because a 25 microgram 
drop (the size of two salt grains) of this colorless 
and odorless fluid anywhere on the skin could 
cause the effects. One ounce is enough to dose 300 
thousand people. The CIA was unable to achieve 
their goals of weaponizing LSD. They were unable 
to control minds or cause permanent insanity by 
dosing personnel. Instead of being controlled or 
damaged, the men had fits of laughter and an 
enjoyment for the nature environments they were in 
(National Geographic Documentary 2009).       
 
Historical Uses of Psychedelics 
 
Psychedelics occur naturally in both animals 
and plants. They have played a significant role in 
the development of philosophy and religious 
thought in earlier cultures. Well documented 
examples of psychedelic use include the soma of 
ancient India, peyote used by Native American 
tribes, rituals by Aztec shamans, ritual use by 
peoples throughout Mexican history, ceremonies of 
the ancient Greeks, and use of ayahuasca in modern 
Brazil (Nichols 2003, p. 133). Psychedelics were 
popular for philosophy development and religious 
use because of their ability to induce states of 
altered perception. These substances were not 
considered “drugs” in these cultures. To find 
references to use in literature, it is important to look 
at key words such as “fruit of the gods,” “divine 
fruit,” or “flesh of the gods.” 
The science of psychedelics became popular 
after new scientific methods for synthesizing 
psychoactive substances became available and new 
techniques for studying them. MDMA was first 
synthesized in 1912 by Merck chemist Anton 
Kollisch (Ecstasy Rising 2004).  
MDMA hadn’t been ingested at that point, so there 
was no indication of its potential effects. Soon after 
Albert Hoffman synthesized LSD at the Sandoz 
pharmaceutical laboratory in 1938, scientific 
interest began to peak in psychedelics. Hoffman 
had accidentally ingested a small amount and 
experienced the world’s first LSD trip (National 
Institute on Drug Abuse 2001). By the 1965 more 
than a thousand peer-reviewed research articles 
detailed the use of psychedelic compounds for 
medical purposes. Promising therapeutic effects 
were reported in over 40,000 subjects who had each 
used LSD in multiple sessions (Vollenweider and 
Kometer 2010, p. 1) (Nichols 2003, p 162) 
(Stafford 1992, p. 40-44). At the same time, 
recreational use was rampant, having been made 
popular by Leary and his associates (Stafford 1992, 
p. 51). The suicide of Diane Linkletter, daughter of 
the entertainer Art Linkletter, after taking LSD was 
one of the major sparks that allowed the passing of 
the Controlled Substance Act of 1970 which put all 
psychedelics on the schedule I list. The media had 
argued that Diane had no personal problems, and it 
was the drug that caused the suicide. While alive 
she was portrayed as a well-educated, Christian, 
white woman with no prior drug use or symptoms 
of depression (Baum 1997, p. 25) (Greenberg 2010, 
p. 256). Rampant use of ecstasy in the 1980s lead to 
the adding of MDMA to schedule I in 1985. The 
Controlled Substance Act and the war on drugs 
interrupted all research until the 1990s, where 
research began to make a slow comeback.  
A recent resurgence of research on these 
substances questions the validity of their schedule I 
classification. Media outlets such as World Report 
and the New York Times have expressed excitement 
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about the psychedelic assisted psychotherapies for 
the treatment of anxiety, depression, post-traumatic 
stress disorder, obsessive compulsive disorder, 
addiction, and more. Tom Roberts, professor of 
educational psychology at Northern Illinois 
University, notes that “What we see now is the 
[US] FDA making decisions based on data rather 
than politics” (Morris 2008, p. 1491). Universities, 
among them Johns Hopkins, Purdue University, 
University of Arizona, Harvard, New York 
University, and U.C.L.A, are obtaining federal 
permission to study these substances, leading the 
way in the United States. Non-profit groups such as 
the Heffter Research Institute and the 
Multidisciplinary Association for Psychedelic 
Studies (MAPS) are also contributing (Tierney 
2010).  
 
Research Supporting Lowering LSD, Psilocybin, 
and MDMA from Schedule I 
 
Since the 1960s, public service announcements 
have been making false claims about LSD and 
Psilocybin that had not been confirmed by ethical 
scientific research, frightening drug effects ranging 
from schizophrenia, chromosome damage, birth 
defects, and murder to suicide (National 
Geographic Documentary 2009). False claims 
about MDMA have included irreversible brain 
damage, Parkinson’s after one pill, and holes in the 
brain (Ecstasy Rising 2004). Current leaders in this 
field, who have performed ethical clinical trials 
with animals and humans, disagree with these 
claims. Their research also shows that these 
hallucinogens meet none of the criteria required for 
schedule I designation. 
 
1) The drug has a high potential for abuse. 
 
Hallucinogens do not engender drug 
dependence or addiction and are not considered 
reinforcing substances. They don’t produce drug-
seeking behavior or physical withdrawal symptoms 
(Nichols 2003, p. 134) (Studerus et al. 2010 p. 2). 
The scientific community argues that dependence 
liability in a drug stems from the ability to affect 
dopaminergic (DA) transmission. “Nearly all 
hallucinogens lack the affinity either for DA 
receptors or for the DA uptake transporter and 
therefore do not directly affect DA 
neurotransmission (Nichols 2003, p 134).” There 
are no literature reports of successful attempts to 
train animals to self-administer hallucinogens, 
indicating that these drugs do not possess the 
necessary pharmacology to initiate or maintain 
dependence (Nichols 2003 p. 134) (Studerus et al. 
2010 p. 14). Results of a clinical study involving 
227 psilocybin sessions with 110 subjects 
conducted between 1999 and 2008, indicate that 
“carefully monitored administration of psilocybin 
to healthy volunteers within an experimental setting 
does not increase the risk of subsequent abuse of 
psilocybin or other illicit drugs (Studerus et al. 
2010, p. 14).” These results are in line with another 
long term study involving LSD. In a ten year follow 
up of 247 subjects who received LSD in an 
experimental or therapeutic setting, most subjects 
reported discontinuing or reducing their 
hallucinogen drug use. Use of hallucinogens tends 
to be less frequent or discontinued over time. 
Regular use is unlikely for several reasons. 
Tolerance develops at a rapid rate (Studerus et al 
2010, p. 14). Hallucinogens, when taken for a 
second consecutive day, do not give the user the 
normal effects. Subjects in the psilocybin study 
reported the effects as being tired. They were glad 
to regain their normal state of consciousness and 
needed time to recharge. Furthermore, 
hallucinogens do not produce the pleasurable 
effects of addictive drugs such as escape, euphoria, 
anxiety relief, increase of self-esteem, etc (Studerus 
et al. 2010, p. 14). 
 
2) There is a lack of safety for use of the drug 
under medical supervision. 
 
“Hallucinogens are generally considered to be 
physiologically safe molecules whose principle 
effects are on consciousness (Nichols 2003, p. 
134).” They do not have harmful physiological 
effects. Hallucinogens are not toxic to any 
mammalian organ systems and there is no evidence 
to suggest that they damage any human organs. 
“Hallucinogens do not cause life- 
threatening changes in cardiovascular, renal, or 
hepatic function because they have little or no 
affinity for the biological receptors and targets that 
mediate vital vegetative functions (Nichols 2003, p. 
134).” Dr. James Gill, Deputy Chief Medical 
Examiner in New York City, conducted a three 
year study in the early 2000s to see how many 
deaths in New York City were related to MDMA 
toxicity. He looked at all the autopsies that were not 
related to any natural causes of death. Out of 
19,000 autopsies, only 22 subjects had MDMA in 
their system. Of these 22 subjects, only two of the 
deaths could be attributed to ecstasy alone. This 
study was conducted at a time when statistics from 
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the DEA reported New Yorkers using 
approximately 110 million doses of ecstasy 
(Ecstasy Rising 2004).  
The primary effect of administering 
hallucinogens to subjects is psychological. LSD 
and psilocybin can induce disturbing experiences. 
They can also catalyze an onset of psychosis or 
depression, which has led (in some cases) to 
suicide. However, these drugs do not appear to 
produce illness in people who are not predisposed 
to those illnesses (Nichols 2003, p. 135). Psychosis 
and depression were catalyzed only in people 
having a genetic predisposition. The actual 
numbers of occurrences for recreational users are 
also low. A search of Medline in 2003 by Dr. 
Nichols for cases of LSD-induced psychosis 
yielded three reports in the previous 20 years 
(Nichols 2003, p. 135). According to the 2006 
National Study on Drug Use and Health, 
approximately 23 million people (9.5 percent of the 
population) over the age of twelve had used LSD in 
their lifetime. 
Risks can be avoided in ethical and 
responsible medical settings. Bad trips can be 
treated with “talk-down” therapy and 
administration of benzodiazepines (Nichols 2003, 
p. 135). Data from the psilocybin study 
demonstrate safety and tolerability in both the short 
term and long term with 227 psilocybin 
administrations.  There is no indication of 
persisting perception disorders, prolonged 
psychosis, or other long-term impairments of 
functioning. A small proportion of “bad trips,” 
were resolved by providing interpersonal support. 
The team concluded “that psilocybin administration 
to healthy, high functioning, and well-prepared 
subjects in a responsible clinical or research setting 
is generally well tolerated and that future studies 
using this important research tool are justified 
(Studerus et al. 2010, p. 16).” The administrations 
were well tolerated, producing positive outcomes. 
The team concluded that hallucinogenic drugs used 
under controlled and supportive conditions can lead 
to,  
“Sustained positive changes in personality, 
attitudes and values, particularly in those 
subjects who have experienced profound 
personal insights and transcendent or mystical 
experiences. Among the most often reported 
are more self-understanding, more tolerance of 
others, less egocentricity, a less materialistic 
and aggressive orientation, and more 
appreciation of music, art, and literature 
(Studerus et al. 2010, p. 14).” 
Much contradictory research that emerged during 
the war on drugs neglected two very important 
concepts regarding hallucinogens. The first is that 
hallucinogens are not predictable like other central 
nervous system drugs. They do not have the same 
effects every time because primary determinants of 
subject experience are expectations (“set”) and 
environment (“setting”) (Nichols 2003, p. 137) 
(Greenberg 2010, p. 164). Hallucinogens do not 
directly cause any behaviors or feelings. They 
amplify the thoughts and emotions of the user and 
are completely vulnerable the user’s “set” and 
“setting.” A negative “set” and “setting” can result 
in a “bad trip” or a disturbing experience.  If a 
clinical or research setting creates a positive “set” 
and “setting,” the experience of the user can be 
sublime. Early research supporting the current 
scheduling of hallucinogens used a very negative 
“set” and “setting” for the subjects. Subjects were 
administered the drugs in very rigid, mechanical, 
and frightening settings. They were strapped  
down to a bed to be poked and prodded with tools 
(National Geographic Documentary 2009). The 
CIA also conducted unethical experiments by 
dosing military soldiers without their knowledge or 
consent. This led to a very small percent of soldiers 
committing suicide via jumping out of windows 
because they falsely believed they became 
permanently insane (Greenberg 2010, p. 164). It 
was the situation which elicited negative reactions 
from the patients, not the drug itself. These 
situations can be controlled. Secondly, different 
doses produce different qualitative effects (Nichols 
2003, p. 137).  
Increasing or decreasing dosage does not 
simply change the amplification of the effects. 
There are different thresholds for different tiered 
effects. For example, there is a certain dose 
required for people to hallucinate on LSD and 
psilocybin. If the dose is lower than that threshold, 
the subject will not have hallucinations. This is 
valuable because the patient can be given a dose 
that can provoke the emotional and perceptive 
effects without causing uncomfortable 
hallucinations. This concept was neglected in 
research aimed to see if hallucinogens could be 
safely administrated.  
 
3) The drug has no currently accepted medical 
use in the United States. 
 
LSD, Psilocybin, and MDMA each have their 
own unique medical applications. They have a 
cross tolerance and several shared effects, but their 
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subtle differences in chemical structure cause them 
to have unique effects, and thus a diversity of 
medical applications. LSD and psilocybin are 
known as Classical Hallucinogens. Classical 
Hallucinogens have a high affinity for serotonin (5-
HT2A) receptors. MDMA does not have the same 
affinity and is not considered a Classical 
Hallucinogen.  There are several potential medical 
applications for administration of these three 
hallucinogens to patients in order treat illness. The 
illnesses which might be effectively treated with 
hallucinogens currently have few highly effective 
treatments available which also include harmful 
side effects, thus necessitating this new innovative 
research. There is also valuable information that 
can be obtained about cognitive neuroscience by 
studying the chemical interactions in the brains of 
healthy subjects under the influence of Classical 
Hallucinogens. 
 
Clinical Applications of Psychedelics 
 
Psychedelic Assisted Psychotherapy 
 
The concept for the technique of psychedelic 
assisted psychotherapies is completely new. 
Psychedelic assisted psychotherapy involves using 
hallucinogens to put patients in an altered mental 
and emotional state which would make a therapy 
session more effective. Dr Roland Griffiths of the 
School of Medicine at Johns Hopkins University 
describes it as, 
“Not about taking psilocybin or other 
compounds multiple times. It’s about 
orchestrating, if you can, a single profound 
transformative experience; that then results  in 
an unfolding of behavioral change over time 
(National Geographic Documentary).” 
These sessions are only meant to happen once or 
very few times and yield results of positive long 
term behavioral change. The whole process has 
several phases. First, the subject must be fully 
diagnosed by a licensed professional. A review of 
the subject’s background and diagnoses will need 
to be analyzed to see if the subject has the 
necessary prerequisites to safely take the drugs 
(Multidisciplinary Association for Psychedelic 
Studies 2005, p. 7). The subjects must then have 
intense preparation before the psychedelic assisted 
session (Vollenweider and Kometer 2010, p. 4). 
The therapist must form a strong therapeutic 
alliance, create a safe psychological and 
physiological space, and prepare the participant 
mentally for the experience. These can be  
accomplished in approximately two ninety minute 
sessions (Multidisciplinary Association for 
Psychedelic Studies 2005, p. 9). The drug assisted 
session will be longer than a typical session. It will 
be multiple hours; depending on which drugs are 
used and how long the effects from the  
dosage is. After the session, it is beneficial for there 
to be drug-free follow up sessions. All three drugs 
of interest, along with other hallucinogens, have 
special qualities for assisting therapy. 
 
MDMA Assisted Psychotherapy 
 
Preliminary trials with MDMA assisted 
psychotherapy have had very high rates of success 
with treating posttraumatic stress disorder. 
“Posttraumatic stress disorder (PTSD) is a 
debilitating anxiety disorder characterized by re-
experiencing, hyperarousal and avoidance 
symptoms, and is a major worldwide public health 
problem (Mithoefer et al. 2010, p. 1).” “Patients 
with PTSD are prone to extremes of emotional 
numbing or overwhelming anxiety, and often have 
a narrow window between thresholds of under and 
over-arousal (Mithoefer et al. 2010, p. 1).” 
According to the 2005 Multidisciplinary 
Association for Psychedelic Studies (MAPS) 
handbook,  
“MDMA can attenuate the fear response and 
decrease defensiveness without blocking 
access to memories or preventing a deep and 
genuine experience of emotion. Participants 
are able to experience and express fear, anger, 
and grief with less likelihood of feeling 
overwhelmed by these emotions. MDMA 
seems to engender awareness that such 
feelings arise as an important part of the 
therapeutic process. In addition, feelings of 
empathy, love, and deep appreciation often 
emerge, along with a clearer perspective of the 
trauma as a past event and a heightened 
awareness of the support and safety that exists 
in the present. Hence, the goal of MDMA-
assisted therapy in treating PTSD is to enable 
the  participant to restructure his/her 
intrapsychic realities and develop a wider 
behavioral and emotional repertoire with 
which to respond to anxiogenic stimuli.” 
Many therapists who have experience performing 
MDMA assisted psychotherapy claim that it could 
accomplish what would take years of therapy in one 
session (Baum 1997, p. 212) (Greenberg 2010, p. 
154). An example of feedback from a patient is that 
the drug helped her  
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confront memories of a rape she suffered, which 
helped her end periods of depression in panic. She 
told Newsweek, “not only did MDMA enable me to 
recover my sanity, it enabled me to  
recover my soul” (Baum 1997, p. 212). MDMA 
assisted psychotherapy is primarily being used for 
PTSD, however it has also shown promise in 
couple’s therapy and mood and anxiety disorders. 
MDMA, while classified as a hallucinogen and 
psychedelic, does not cause psychotic-like states or 
hallucinations like LSD or psilocybin. 
Possible theories about the chemical 
mechanism for MDMA are that MDMA releases 
serotonin, stimulates the serotonin (5-HT2) 
receptor, and increases the neurohormones 
oxytocin, prolactin and cortisol. The mood and 
perception lifts are caused by the serotonin release 
(Mithoefer et al. 2010, pg. 3). “Findings suggest 
that oxytocin is involved in affiliation, trust, and 
accurate perception of emotion, so elevated 
oxytocin might help participants form a therapeutic 
alliance and revisit traumatic experiences in an 
emotionally engaged state (Mithoefer et al. 2010, p. 
3).” It was also found that oxytocin reduced 
activation of the amygdale in humans, which is 
responsible for fear emotions. A recent study also 
found that elevation of oxytocin was associated 
with greater sociability and gregariousness 
(Mithoefer et al. 2010, p. 3).   
 
LSD and Psilocybin Assisted Psychotherapies 
 
LSD and psilocybin have different effects than 
MDMA because they agonize different serotonin 
receptors. They both primarily agonize the 
serotonin (5-HT2A) receptor which plays a major 
role in their medical applications. Researchers 
believe LSD and psilocybin may be useful in 
treating depression, anxiety, and Obsessive 
Compulsive Disorder (OCD) as an adjunct to 
therapy. Several universities, including New York 
University, Johns Hopkins University, and 
University of California have had a lot of success 
with treating anxiety and depression in  
terminally ill cancer patients (Vollenweider and 
Kometer 2010, p. 3). Studies from the 1960s 
concluded that LSD treatment resulted in improved 
psychological adjustment in dying patients,  
made them more responsive to their families and 
environments, and enhanced their ability to enjoy 
every-day life. Later studies at Spring Grove State 
Hospital in Maryland showed improvement in 
about two-thirds of the cancer patients who had 
received LSD. Some of these reported 
improvements were improved mood, reduced fear 
of death, and reduction in the amount of pain-
relieving medication required. Half of patients 
reported dramatic improvement and profound 
experiences (Nichols 2003, p. 163). Dr. Charles 
Grob and his assistant Alicia Danforth conducted 
an end of life study at Harbor UCLA Medical 
Center which involved giving psilocybin assisted 
psychotherapy to twelve terminally ill patients. 
Terminally ill patients can be overwhelmed with 
anxiety and fear about their upcoming death. They 
also are typically on a lot of pain medication and 
are in medical environments which restrict them 
from appreciating life. Before dying, the patients 
reported positive mood shifts and increased 
acceptance of death. They had mended 
relationships and were able to spend quality time 
with their families (National Geographic 
Documentary 2009). 
There are several theories for possible 
mechanisms to explain how classic hallucinogens 
improve therapy. Scientists estimate that the brain 
takes in eleven million bits of information per 
second; however, the brain can only process about 
two hundred bits at a time. To handle that amount 
of information, the brain must filter out information 
that is not critical. It does this by connecting new 
information to preconceived concepts so that it 
does not have to analyze all of it (National 
Geographic 2009). Dr. Torsten Passie’s “Hollow 
Mask Study” at the Hannover Medical School in 
Germany concluded that schizophrenics and 
subjects intoxicated by LSD do  
not process information in that same way. The 
filters are lifted and the ability to connect new 
information to preconceived concepts is 
temporarily suspended. This means psychedelics  
temporarily de-condition the mind, resulting in the 
ability to take in more information, more sensory 
impression, more emotional impression, more 
visual impression, and more access to parts of the 
mind (National Geographic Documentary 2009). 
This allows the LSD user to approach problems in a 
more genuine and open minded way that neglects 
socially conditioned behaviors or roles. The 
increased mind power and stimulation comes from 
the increased activity of the serotonin (5-HT2A) 
receptor. 
Activation of serotonin (5-HT2A) receptors 
initiates complex chemical reactions in the pre-
frontal cortex. LSD and psilocybin have such a 
similar shape to serotonin molecules that they are 
able to fit in the receptor like a lock and key. 
Serotonin (5-HT2A) receptors are located on the 
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large glutamatergic pyramidal cells in the deep 
cortical layers. The chemical reactions from 
binding with the serotonin (5-HT2A) receptors 
releases glutamate across the synapse, which then 
activates the AMPA (α-amino-3-hydroxy-5-methyl-
4-isoxazole propionic acid) and NMDA (N-methyl-
d-aspartate) receptors on the cortical pyramidal 
neurons.  In addition, LSD and psilocybin directly 
activate the serotonin (5-HT2A) receptors located 
on cortical pyramidal neurons. The synergy of 
activating the serotonin (5-HT2A), AMPA, and 
NMDA receptors on the cortical pyramidal neuron 
results in the increased expression of brain-derived 
neurotrophic factor (BDNF) (Gonzalez-Maeso and 
Sealfon 2009, p. 227) (Vollenweider and Kometer 
2010, p. 5).  BDNF is a chemical that promotes the 
growth and survival of neurons. A deficiency in 
BDNF may impair the health of neurons and lead to 
depression (Comer 2010, p. 250). Since serotonin 
(5-HT2A) receptors are linked to the prefrontal 
cortex, this means Classical Hallucinogens lead  
to increased neuron strength in the prefrontal cortex 
from the BDNF.  Areas in the prefrontal cortex are 
responsible for complex mental functions such as 
cognition, mood, perception, self  
control, and somatic awareness (Nichols 2003, p. 
162). The increased effectiveness of therapy may 
be derived from a boost of brain metabolism and 
strength in these mental functions. 
 
Administration to Patients: LSD and Psilocybin for 
Treatment of Cluster Headaches 
 
John Halpern’s research, at the McLean 
Hospital at Harvard Medical School, illustrates that 
LSD and psilocybin may have a high success rate 
for reliably treating cluster headaches. Cluster 
headaches are severely painful and debilitating 
headaches that reoccur. Scientists do not fully 
understand what causes cluster headaches, but they 
know it is related to blood vessels, nerves and 
neurochemistry. There is no cure and few 
treatments. The available treatments, including 
oxygen and/or medication, are minimally effective. 
The mechanism is unknown, but LSD and 
psilocybin seem to be highly effective in relieving 
or eliminating cluster headaches. A survey by 
Halpern indicated that for 53 subjects, psychedelics 
prevented or stopped cluster headaches more 
reliably than medication. Halpern and his 
colleagues at the Hannover Medical School in 
Germany launched a clinical trial on six subjects 
with cluster headaches. The team developed a non-
psychedelic form of LSD, LSD-BROMO, and 
administered it three times over a fifteen day 
period. For five of the six participants the 
headaches were gone. All of the participants 
reported that their quality of life had totally 
changed (National Geographic Documentary2009).  
The addition of a BROMO molecule to LSD 
creates a molecule that is too big to fit in the 
receptors that would normally trigger intoxication. 
LSD-BROMO successfully relieves cluster 
headaches in the same way other LSD molecules 
do, except it has no hallucinogenic properties.  
Despite displaying no hallucinogenic properties, 
LSD-BROMO was added to schedule I and is 
illegal in the United States; thus restricting research 
and clinical trials. Since This trial, no further  
clinical trials have been funded to administer LSD, 
psilocybin, or non-hallucinogenic LSD-BROMO to 
treat cluster headaches (National Geographic 
Documentary 2009).   
 
Understanding Cognitive Neuroscience through 
LSD-Like Intoxication in Healthy Subjects 
 
LSD-like hallucinogens, including psilocybin 
but not MDMA, are psychotomimetic at high 
doses; meaning they induces psychotic like 
episodes (Gonzalez-Maeso and Sealfon 2009, p. 2) 
(Nichols 2003, p. 162). There are a wide variety of 
hallucinogens that mimic different types of 
psychotic symptoms and disorders. The effects are 
contingent on how the molecules are shaped and by 
what receptors they either agonize or antagonize. 
LSD in particular mimics the positive symptoms of 
schizophrenia (hallucinations and thought 
disorder). Psychotomimetic hallucinogens can be 
used as tools for understanding neuronal basis of 
psychiatric disorders, understanding a psychotic 
experience, and finding a cure for those psychiatric 
disorders (Vollenweider and Kometer 2010, p.1). 
Franz Vollenweider uses neuroimaging technology 
at the University Hospital of Psychiatry in Zurich to 
map brains on psychedelics. His data shows that a 
brain on hallucinogens looks the same every time 
(National Geographic Documentary 2009). This 
means clinical trials with psychotomimetics are 
reliable to be analyzed and compared for 
conclusions.  
Schizophrenia is very difficult to treat and 
learn about because some of the symptoms make 
fruitful communication between the patient and 
doctor impossible. Formal thought disorders, loose 
associations, derailment, poverty of speech, 
avolition, and social withdrawal make verbal 
communication very difficult (Comer 2010, p. 
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462). LSD-like hallucinogens can help researchers 
and doctors learn more about the schizophrenic 
experience by taking it themselves or performing 
clinical trials. Once the subject is sober, they will 
have their previous mental capacity and intelligence 
restored and be able to articulate their experience in 
a more accurate way than a patient with a 
permanent psychopathology. Dr. Charles Nichols, 
Geneticist from the LSU Health Sciences Center, 
also believes “by understanding how LSD produces 
its effect at the molecular and genetic level, we 
could potentially understand mechanisms 
underlying diseases like psychosis that have very 
similar overlapping behaviors (National 
Geographic Documentary 2009).” By 
understanding the neurochemical and genetic 
causes of psychosis, psychopharmacologists could 
potentially be able to create drugs that negate those 
causes in order to treat psychosis more effectively. 
One possible problem with finding treatments 
for certain psychotic disorders, such as 
schizophrenia, is that they are uniquely human 
disorders (Gonzalez-Maeso and Sealfon 2009, p. 
1). This means there are no animal models to do 
tests on. Animal test subjects are crucial because 
scientists can perform tests on them that would be 
unethical for human subjects. They can be bred to 
control for variables and provide a larger supply of 
test subjects. Hallucinogens fix this problem 
because they give opportunities to test 
schizophrenic-like mice. According to Dr. Nichols, 
LSD induced mice display human symptoms of 
schizophrenia. This gives him the ability to study 
brains of schizophrenic mice and test potential 
treatments on them (National Geographic 2009). 
They can induce mice with schizophrenic episodes 
and test anti-psychotics to see if they bring the mice 
back to a normal state of health. 
Hallucinogens agonize and antagonize various 
serotonin receptors, among other neurotransmitters. 
The serotonin receptors in particular that 
hallucinogens interact with affect complex parts of 
the human brain, including much activity in the 
prefrontal cortex and interconnecting pathways 
between the cerebral cortex and limbic systems 
(brain regions implicated in pathophysiology of 
many mental disorders) (Gonzalez-Maeso and 
Sealfon 2009. p 228). Pathology relating to mood 
and anxiety is associated with an imbalance or 
abnormal functioning of serotonin chemical 
reactions.  Thus, testing and understanding the 
mechanisms of hallucinogens may lead to 
important clues for the basis of psychosis. The 
results obtained from the mechanism of Classical 
Hallucinogens may provide efficient approaches for 
the rational design and testing for new types of 
antipsychotic drugs (Gonzalez-Maeso and Sealfon 
2009, p. 225). This also means experimental use 
with hallucinogens can be a great aid for mapping 
out the brain and further understanding the 
prefrontal cortex, pyramidal cells, serotonin, 
glutamate NMDA, AMPA, and BDNF interactions.  
 
Methodology 
 
Semi-structured interviews were conducted 
with a snowball sample of subjects to learn about 
their experiences with MDMA, LSD and 
psilocybin. The subjects were recruited privately 
through networking within the drug using 
community. Six public liberal arts College students 
were selected because of their high level of 
experience with the substances of interest. Five of 
the subjects were male and one was female. The 
goal of the interviews was to evaluate if the effects 
of MDMA, LSD, and psilocybin were recreational 
or entheogenic. The operational definition for 
“recreational experience” is experiences that cause 
altered physical and mental effects during 
intoxication. However, after the substance has been 
processed and excreted from the body, the subject 
retreats to their previous physical and mental states 
prior to intoxication. The operational definition of 
“entheogenic experience” is long term 
transformative effects on personality, spirituality, 
cognitive state, emotional state, and perception of 
one’s self after intoxication. 
The interviews ranged from twenty minutes to 
an hour in length. The interviews were conducted at 
each subject’s home for comfort and privacy. To 
prevent coding bias, the interviews were recorded 
on a handheld recorder and later transcribed. The 
subjects gave verbal consent on the recorder. The 
recordings were deleted after transcription to 
protect the subject’s from being identified by their 
voice. No names or information that could be used 
to identify the subjects were used. The interviews 
had a pre-set list of questions; however, the 
subjects had freedom to discuss details beyond the 
scope of the pre-set questions. The subjects were 
asked questions about three different phases related 
to their drug use. They were asked questions about 
their experiences leading up to their first time uses 
with these drugs. They were asked questions about 
the experiences and feelings while intoxicated by 
these drugs. Finally they were asked about their 
experiences and reflections after their intoxication 
had ceased.  
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The subjects had varying levels of experience 
with each drug. 
 
Bar Chart: Subject’s estimate of experiences using 
Psilocybin (left bars), MDMA (middle bars) and 
LSD (right bars). Each subject had at least twelve 
combined experiences with the drugs of interest. 
All of the subjects reported doing some type of 
research before having their first experience with 
these hallucinogens. They approached these drugs 
with skepticism and caution because of the negative 
stigma associated with them. Each subject used 
sources such as books, encyclopedias, friends who 
had experience, and online sites for information 
about what to expect and how to approach the 
experience. All of the subjects mentioned using 
erowid.com for anecdotes, information about 
appropriate doses, and advice for activities to do 
while intoxicated. 
Subject 5 (female) appeared to have 
recreational experiences while the rest of the 
subjects appeared to have, for the most part, 
entheogenic experiences. This can be explained by 
their different habits of use. Subject 5 typically 
took lower than average drug doses, which since 
hallucinogens have different qualitative affects at 
different dose levels, gave her less intense 
effects compared to the other users. She used the 
drugs to make regular recreational activities, such 
as dancing to music, more enjoyable. 
 Subjects 1,2,3,4, and 6 used hallucinogens 
differently than subject 5. They took higher doses 
and created their own private ritual-like 
experiences. They tended to avoid large social 
situations; instead, they spent their experiences in 
small groups and in environments where they felt 
safe and comfortable. 
 
Effects and Experiences While Intoxicated 
 
Subject 5 used MDMA and LSD as party 
drugs. She used them to enhance social 
experiences. It enables her to connect with people 
more easily and with more depth. “On ecstasy I just 
love everyone.” The euphoria also amplifies the 
pleasure of music, colors and dancing. She also 
reported a greater connection with nature on LSD 
and psilocybin. The effects of the  
hallucinations were not as intense due to the 
relatively low doses she used. She described her 
environment as being “wavy” and “breathing.” 
Since the effects were not too intense, they were 
always very manageable. She claimed to feel very 
safe and confident in her drug use. 
Subjects 1,2,3,4, and 6 had different 
experiences than subject 5. Their experiences were 
more intense and more varied. They reported 
having few negative moments in their experiences, 
but they were always able to calm themselves or 
each other down during those unfavorable intense 
moments. Aside from those few moments, they 
report overwhelmingly positive transformative 
experiences. They were very introspective. 
According to subject 4, 
“Whatever your feeling becomes dramatic and 
exaggerated and richer than you’ve ever 
experienced before. You kind of see your dark 
side and light side. You see your persona for 
what it is; for all its sincerity and bulls***. 
You see your shadow for what it is. You see 
your entire personality almost from an outside 
perspective and I think part of being on acid is 
losing that sense of judgment of positive and 
negative and ultimately coming to the 
conclusion that this is who you are. And as far 
as today goes, you’re not going to change it. 
So you might as well embrace it.”   
Subject 4 also reported the “[he] dance[s] across the 
entire emotional spectrum, but [he] does it with the 
volume turned all the way up.” He later said that he 
has experienced a range from ecstatic bliss to 
depressive nihilism. 
Subject 1, when talking about LSD reported, 
“The way I experience the world is that 
everything is more beautiful. I’ll just see 
something like a leaf with a dew drop on it and 
just love the natural beauty of it. Everything 
around just seems more vivid and I’m 
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generally pretty happy. I’ve never had  a bad 
trip.” 
Subject 1 takes SSRIs, however, he reported a 
better mood lift with acid. “If I could take acid once 
a month, I could be content with the whole month.” 
The enthogenic subjects not only experienced 
introspective self-analyses, but also examined their 
relationships with family and friends. They 
reported that hallucinogens have been important 
aids in repairing or strengthening relationships. 
Four out of the five entheogenic users had specific 
anecdotes on how hallucinogens played a positive 
role in their relationships. Subject 1 reported, 
“A couple of years ago I was having a fight 
with my girlfriend and I just took a couple of 
tabs of acid, probably not the best idea to do in 
that situation. I just went alone and did acid 
with a friend. It made me feel like, why am I 
fighting with my girlfriend? I should just go 
and make amends because it’s stupid. I kind of 
felt love for everybody.” 
Subject 2 had an elaborate intimate experience with 
his significant other which he attributed 
to MDMA. They both took MDMA at his house. 
“She was nervous at first. As we were coming 
up I comforted her and she became more 
comfortable with the sensation. From that 
point until we came down it was just heaven. 
We laid around in my room in our underwear 
and we just talked. We talked about  each 
other and who are some people important in 
our lives. The whole experience centered 
around her and I and we really connected. And 
there are things that people say to each other, 
or don’t say to each other rather. Like when 
you say very emotionally charged things to 
somebody you care about; sometimes you’re 
apprehensive about overstating your 
appreciation for them to avoid maybe 
cheapening the relationship or feeling that you 
have for them. I think MDMA really let us say 
these things to each other and really mean it 
and understand that the other meant it. Like I 
said, sometimes you avoid saying  these things 
to avoid cheapening what they mean and other 
times you simply don’t get around to saying it 
them due to circumstances or timing or 
whatever. It let everything out that needed to 
come out. It was really instrumental in us two 
making that connection.” 
Subjects 3 and 6 talked about psilocybin 
experiences that elicited strong positive emotional  
feelings about family members. Subject 3 reported, 
 
“One of my first experiences with psilocybin 
was at a concert and I remember enjoying the 
music very much. But at one point in the 
concert, I had just stopped and found my mind 
wondering and daydreaming. I was thinking 
about the relationship I had with my mother at 
the time. I didn’t particularly like the way the 
relationship was going and so in the calm state 
I was in I wondered, Why isn’t that better? 
Why don’t I better that  relationship?” 
Subject 6 detailed one of his psilocybin 
hallucinations and emotions associated with it. 
“My next journey was with my girlfriend. We 
were dressed like Adam and Eve in a forest. 
We held each other and spiraled into the green 
and blue corners of space and time. It wasn’t 
erotic. It was a spiritual connection. I felt close 
to her. I felt one with her. I thought about my 
family. I connected with their spirits. Our 
energies became one. There  was no more 
sadness. All problems ceased to exist. I met 
my father and we were free.”  
 
Post Experience Reflections 
 
There were several common reflections among 
the subjects. All of the subjects feel safe, secure 
and confident with these drug experiences. They 
are all open-minded to using these substances again 
in the future. They are so confident in their 
experience and understanding of the drugs that they 
would feel comfortable recommending use to a 
friend or loved one. All of the users also reported 
having no regretted experiences on these 
substances. They felt the negative moments had 
value to their development and character. 
The entheogenic users also had some common 
sentiments. They felt that their experiences with 
these drugs had a very positive impact on their 
relationships, mood, outlook on life, and creativity. 
They use these drugs primarily for spiritual and 
emotional development. They did not use 
frequently; rather, they decided to use at key 
moments in their life where they were struggling, 
had big decisions to make, or wanted to bond with 
friends. 
 
Conclusion 
 
Hallucinogens have a long history of being 
used by humans for spirituality and well-being. The 
act of moving hallucinogens to schedule I with the 
Controlled Substance Act was hasty and poorly 
thought out. This decision interrupted much needed 
10
Proceedings of GREAT Day, Vol. 2011 [2012], Art. 25
https://knightscholar.geneseo.edu/proceedings-of-great-day/vol2011/iss1/25
 261
research into mental health and well-being. Current 
projects offer data that supports the lowering of 
hallucinogens from schedule I to a level that would 
continue to prohibit recreational use, while 
permitting research and medical use. There is 
overwhelming evidence that hallucinogens do not 
meet the criteria set by the Controlled Substance 
Act to be ranked as schedule I. Hallucinogens have 
a very low potential for abuse. They are one of the 
least addictive drugs that exist. They can be safely 
used in a medical situation because of a lack of 
toxicity and addiction. With the appropriate dose, 
set and setting, a licensed professional can create a 
safe and controlled environment for patients to use 
in a medical situation. The literature also shows 
that there are many potential medical uses in the 
United States from psychedelic assisted 
psychotherapy for the treatment of mood and 
anxiety disorder and Classical Hallucinogens for 
the treatment of cluster headaches, to clinical trials 
to aid in the creation of more efficient medications. 
The research is in its preliminary stages and 
has not had many large trials. Much work needs to 
be done on understanding the mechanisms for how 
the drugs affect the brain and behavior at the 
molecular level. Success of preliminary studies 
justifies larger scale double blind trials. Results 
justify increased access to funding and permission 
for research institutions to use these substances in 
clinical trials. 
The interviews support the literature and 
illustrate that it may be possible to orchestrate 
possible healthy and positive experiences with 
these drugs. Recreational users may not always 
give accurate insight or judgment about these drugs 
because street drugs are un-regulated. The drug’s 
purity is unknown to the recreational user. Despite 
this flaw, the subjects interviewed did display 
characteristics predicted by the literature. Subject 
5’s description of how she feels on LSD is in line 
with Dr. Passie’s conclusions from the “Hallow 
Mask Studies.” It supported the mechanism by 
which LSD takes off the filters and allows a person 
to evaluate themselves or a situation in a new way. 
This account also illustrated the significance of 
“set” and “setting” because subject  described how 
he feels a whole range of emotions instead of the 
same ones every time. All of the subjects displayed 
how hallucinogens can be a positive influence on 
mood. The anecdotes from Subjects 1, 2, 3, and 6 
illustrated how hallucinogen helped them in their 
relationships. This supports the hypothesis that 
psychedelic assisted psychotherapy may be 
effective in couples therapy or family therapy. 
Research into techniques for psychedelic 
assisted psychotherapy is imperative because they 
may be faster, safer and more effective than 
alternative methods used today; such as anti-
depressants and other medications. According to 
Greenberg, anti-depressants fail to outperform 
placeboes in clinical trials nearly half the time. 
They appear to make a positive difference in 
approximately 60 percent of the people who take 
them, while having serious side effects such as 
suicide (Greenberg 2010, p. 8). Mental health 
patients need newer treatments that are more  
effective, just as fast and without the serious 
potential side effects that exist with current 
medications.  
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